Valuation : Novavax, Inc.

Market Cap 1.53B 1.32B 1.23B 1.13B 2.12B 146B 2.13B 14.64B 5.71B 73.69B 5.73B 5.61B 244B P/E 2026 *
-14.8x
P/E 2027 * -41.3x
Enterprise Value 1.75B 1.5B 1.41B 1.29B 2.43B 167B 2.43B 16.74B 6.53B 84.26B 6.56B 6.41B 279B EV / Sales 2026 *
4.68x
EV / Sales 2027 * 6.88x
Free-Float
93.05%
Yield 2026 *
-
Yield 2027 * -
1 day+2.32%
1 week+3.58%
Current month+26.50%
1 month+25.64%
3 months-10.27%
6 months-8.68%
Current year+37.80%
1 week 8.26
Extreme 8.26
9.58
1 month 7.22
Extreme 7.215
9.58
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 22/01/2023
Director of Finance/CFO 60 15/08/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Director/Board Member 73 05/08/2010
Director/Board Member 66 31/10/2018
Director/Board Member 60 15/06/2020
Date Insider Type Main position Quantity % Market Cap.
20/06/26 Fiscal year

Director

37,760 0.0230%
18/06/26 Free

Director

35,450 0.0216%
25/04/26 Fiscal year

Director

19,040 0.0117%
Change 5-day change 1-year change 3-year change Capi.($)
+2.32%+3.58%+22.16%+10.90% 1.53B
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.15%-0.59%+73.58%+103.66% 27.61B
Weighted average by Cap. -1.68%-1.03%+95.28%+132.91%

Financials

2026 *2027 *
Net sales 373M 321M 301M 275M 518M 35.64B 520M 3.57B 1.39B 17.99B 1.4B 1.37B 59.66B 266M 229M 215M 196M 370M 25.44B 371M 2.55B 995M 12.84B 999M 978M 42.58B
Net income -108M -92.67M -86.89M -79.32M -149M -10.28B -150M -1.03B -402M -5.19B -404M -395M -17.2B -37.93M -32.68M -30.64M -27.97M -52.7M -3.62B -52.86M -364M -142M -1.83B -142M -139M -6.07B
Net Debt 219M 189M 177M 162M 304M 20.93B 305M 2.1B 819M 10.57B 822M 804M 35.03B 303M 261M 245M 224M 421M 28.98B 423M 2.91B 1.13B 14.63B 1.14B 1.11B 48.51B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
28/08/26 US$9.260 +2.32% 4,210,797
27/08/26 US$9.050 -1.74% 3,426,679
26/08/26 US$9.210 -2.44% 3,514,522
25/08/26 US$9.440 +6.55% 7,107,633
24/08/26 US$8.860 -0.89% 5,579,176
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
9.260USD
Average target price
14.00USD
Spread / Average Target
+51.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock